1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Soft Tissue Neoplasms

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Soft Tissue Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A	1

Trials

1 trial(s) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Soft Tissue Neoplasms

Article	Year
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cathepsins; Combined Modality Therapy; Cyclosporine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Soft Tissue Neoplasms; Treatment Outcome; Yttrium Radioisotopes	2005

Article

Year

High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16

Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cathepsins; Combined Modality Therapy; Cyclosporine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Soft Tissue Neoplasms; Treatment Outcome; Yttrium Radioisotopes

2005